Lipid Management with Combination Therapy

Introduction to Combination Therapy

The American College of Cardiology recommends using fenofibrate over gemfibrozil when combining with a statin due to a significantly lower risk of myopathy and rhabdomyolysis, with approximately 15 times fewer adverse events reported per million prescriptions 1, 2
The American Heart Association also recommends fenofibrate over gemfibrozil for statin-fibrate combination therapy due to a significantly lower risk of myopathy and rhabdomyolysis, with substantial evidence from the FIELD study and ACCORD study supporting the safety of fenofibrate in combination with statins 1

Risk factors for myopathy with combination therapy include advanced age, female gender, small body frame, multisystem disease, multiple medications, and perioperative periods 3, 2
The American College of Cardiology suggests avoiding combination therapy in patients with multisystem disease or multiple medications when possible, and using caution with gemfibrozil in thin or frail elderly patients due to increased risk of myopathy 3, 2, 4
Elderly patients, particularly older thin or frail women, and patients with diabetes combined with chronic renal failure should be monitored more carefully when taking the atorvastatin-fenofibrate combination due to a higher risk of myopathy 2

Gemfibrozil inhibits statin metabolism through inhibition of CYP2C8, inhibition of OATP1B1/3-mediated hepatic uptake, and interference with statin glucuronidation, increasing the risk of myopathy approximately 15-fold 1
Fenofibrate has minimal effect on statin metabolism, making it a safer choice 1
Moderate statin doses are recommended rather than maximum doses when combining with fibrates 3, 2
The following dose adjustment guidelines are recommended for fenofibrate:
eGFR (mL/min) Fenofibrate Dose
30-59 ≤54 mg/day
<30 Discontinue use
5, 6
Gemfibrozil should not be initiated in patients on statin therapy due to increased risk of muscle symptoms and rhabdomyolysis 5

eGFR (mL/min)	Fenofibrate Dose
30-59	≤54 mg/day
<30	Discontinue use

Baseline assessments should include muscle symptoms, liver function tests, and renal function assessment before starting combination therapy 2
Follow-up evaluations should include monitoring muscle symptoms, liver function, and renal function at regular intervals, with CK measurements when patients report muscle symptoms 2
Monitor liver function tests at baseline, approximately 12 weeks after initiation, and annually or more frequently if indicated, according to the American College of Cardiology 2
Evaluate renal function before starting fenofibrate, within 3 months after initiation, and every 6 months thereafter, as recommended by the American College of Cardiology 5

Combination therapy should only be used when benefits from ASCVD risk reduction or triglyceride lowering outweigh potential risks, according to the American College of Cardiology 5
Combination therapy should be temporarily withheld during major surgery, as recommended by the American College of Cardiology 3, 2
The American Diabetes Association recommends considering combination therapy for patients with complex dyslipidemias, severe hypertriglyceridemia, metabolic syndrome, or diabetes mellitus with atherogenic dyslipidemia 1, 7
Both gemfibrozil and fenofibrate are recommended as first-line agents for hypertriglyceridemia in HIV patients on antiretroviral therapy, as stated by the Infectious Diseases Society of America 4
Both agents can be used in diabetic patients with dyslipidemia, as recommended by the American Diabetes Association 8
Alternative lipid-lowering agents, such as niacin (vitamin B3) and omega-3 fatty acids (fish oils), are available for patients who cannot tolerate statins or fibrates, as reported by the American Heart Association and American Diabetes Association 4, 8